Scholarlink

Background <p>Breast cancer (BC) is a complex malignancy, impacting a considerable number of women worldwide. Devastating evidence annotated the contribution of dysregulated non-coding RNAs in the evolution and diagnosis of BC. Bioinformatics analyses were employed to select the markers; long non-coding RNA tumor suppressor candidate 7 (TUSC7), its target miR-616, and the associated tumor suppressor Sex Determining Region Y-Box 7 (SOX7) as potential therapeutic targets in BC pathogenesis and metastasis, pertaining to their predictive and discriminating capacities. Herein, 100 subjects were enrolled; 60 BC patients (40 non-metastatic, 20 metastatic), along with 20 fibroadenoma patients, and 20 healthy volunteers.</p> Results <p>Serum TUSC7 and SOX7 were significantly downregulated, whereas miR-616 was significantly upregulated in BC patients versus both controls and fibroadenoma patients. As well, these alterations were more prominent in metastatic versus non-metastatic BC patients. ROC analysis identified SOX7 as an excellent discriminator between BC patients and controls (AUC = 0.91, <i>p</i> &lt; 0.0001) and between metastatic and non-metastatic cases (AUC = 0.766, <i>p</i> = 0.0009). Meanwhile, TUSC7 demonstrated an outstanding discriminative power between BC and fibroadenoma (AUC = 0.933, <i>p</i> &lt; 0.0001). Furthermore, univariate and multivariate logistic analyses revealed the capabilities of TUSC7, miR-616, and SOX7 as significant predictors of BC risk; meanwhile, only SOX7 was identified as a significant predictor of BC metastasis. Combining TUSC7, miR-616, and SOX7 in a predictive panel showed substantial diagnostic accuracy for BC (AUC = 0.978, 95% CI = 0.9567–1.000, <i>p</i> &lt; 0.0001).</p> Conclusion <p>Collectively, this study configures TUSC7/miR-616/SOX7 panel as a novel prospective biomarker and therapeutic target&#xa0;for BC and accentuates SOX7 as a potential predictor of tumor aggressiveness and metastatic behavior.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating lncRNA TUSC7 and its targets miR-616/SOX7 as diagnostic and prognostic panel for early detection and metastatic progression of breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Tarek Kamal Motawi,
  • Dina Hussien Bakry,
  • Olfat G. Shaker,
  • Nevine Fathy

摘要

Background

Breast cancer (BC) is a complex malignancy, impacting a considerable number of women worldwide. Devastating evidence annotated the contribution of dysregulated non-coding RNAs in the evolution and diagnosis of BC. Bioinformatics analyses were employed to select the markers; long non-coding RNA tumor suppressor candidate 7 (TUSC7), its target miR-616, and the associated tumor suppressor Sex Determining Region Y-Box 7 (SOX7) as potential therapeutic targets in BC pathogenesis and metastasis, pertaining to their predictive and discriminating capacities. Herein, 100 subjects were enrolled; 60 BC patients (40 non-metastatic, 20 metastatic), along with 20 fibroadenoma patients, and 20 healthy volunteers.

Results

Serum TUSC7 and SOX7 were significantly downregulated, whereas miR-616 was significantly upregulated in BC patients versus both controls and fibroadenoma patients. As well, these alterations were more prominent in metastatic versus non-metastatic BC patients. ROC analysis identified SOX7 as an excellent discriminator between BC patients and controls (AUC = 0.91, p < 0.0001) and between metastatic and non-metastatic cases (AUC = 0.766, p = 0.0009). Meanwhile, TUSC7 demonstrated an outstanding discriminative power between BC and fibroadenoma (AUC = 0.933, p < 0.0001). Furthermore, univariate and multivariate logistic analyses revealed the capabilities of TUSC7, miR-616, and SOX7 as significant predictors of BC risk; meanwhile, only SOX7 was identified as a significant predictor of BC metastasis. Combining TUSC7, miR-616, and SOX7 in a predictive panel showed substantial diagnostic accuracy for BC (AUC = 0.978, 95% CI = 0.9567–1.000, p < 0.0001).

Conclusion

Collectively, this study configures TUSC7/miR-616/SOX7 panel as a novel prospective biomarker and therapeutic target for BC and accentuates SOX7 as a potential predictor of tumor aggressiveness and metastatic behavior.

Graphical abstract